Published • loading... • Updated
AstraZeneca Quarterly Net Profit Rises 2% On Strong Cancer Drug Sales
- On Monday, July 27, 2026, AstraZeneca backed its annual and long-term forecasts after topping second-quarter profit expectations, reporting core earnings of $2.63 per share and total revenue of $15.38 billion.
- Oncology and rare disease divisions drove growth, with oncology revenues rising 15% to $14.12 billion, which helped offset an 11% drop in Farxiga sales.
- Despite an unexpected trial failure this month, CEO Pascal Soriot remains confident in the company's pipeline, stating, "We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months."
- JPMorgan analysts noted Monday that AstraZeneca is on track to reach its $80 billion annual revenue target by 2030, with full-year revenue expected to increase 5% to 9%.
- Underlying R&D spending ticked up 5% to $3.7 billion, representing 24% of revenues; Derren Nathan, head of equity research for Hargreaves Lansdown, noted improving margins do not compromise future growth investment.
Insights by Ground AI
Podcasts & Opinions
30 Articles
30 Articles
AstraZeneca recorded an increase in revenues and profits in the second quarter, driven by strong sales performance in the oncology segment. Exclusive material for subscribers. To have full access, access the link of the material and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources30
Leaning Left1Leaning Right6Center13Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
C 65%
R 30%
Factuality
To view factuality data please Upgrade to Premium
